<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-047928</identifier>
<setSpec>1137-6821</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">The pacemaker implantation in the Torsade de Pointes: a therapeutic or ethiologic weapon?</dc:title>
<dc:description xml:lang="en">The Torsade de pointes (TdP) is a frequent cause of sudden death of cardiac origin, however, its electrophysiology and treatment are not still clearly established. We communicate a case of a patient with pacemaker implantation that presented various episodes of Torsade of Pointes (TdP) those were efficiently corrected with overdrive pacing and sulphate of magnesium iv. The cause of the prolonged QT interval and the start of this arrhythmia could be favored by the stimulation in epicardium of its pacemaker. We want to impact in the overdrive pacing as efficient treatment of the TdP, and we must value the risk-benefit in the establishment of determined pacemaker&#146;s types in patients at the risk of prolonged QT interval and secondary sudden death by TdP (AU)</dc:description>
<dc:creator>Alonso Formento, E</dc:creator>
<dc:creator>Galve Royo, F</dc:creator>
<dc:creator>Martínez Burgui, J. A</dc:creator>
<dc:creator>Martínez Oviedo, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La torsade de pointes (TdP) es una causa frecuente de muerte súbita de origen cardiaco, sin embargo, su electrofisiología y tratamiento no están todavía claramente establecidos. Comunicamos el caso de una paciente portadora de marcapasos que presentó varios episodios de taquicardia helicoidal o TdP, que fueron eficazmente corregidos con sobreestimulación cardiaca de su marcapasos y sulfato de magnesio iv. La causa de la prolongación del QT y el inicio de esta arritmia pudo estar favorecido por la estimulación epicárdica de su marcapasos. Queremos incidir en la sobreestimulación cardiaca como tratamiento eficaz de la TdP, y en la necesidad de valorar el riesgobeneficio en la implantación de determinados tipos de marcapasos en pacientes con riesgo de prolongación del intervalo QT y muerte súbita secundaria a TdP (AU)</dc:description>
<dc:source>Emergencias (Sant Vicenç dels Horts);18(4): 250-253, jul. 2006. ilus, tab</dc:source>
<dc:identifier>ibc-047928</dc:identifier>
<dc:title xml:lang="es">El marcapasos en la Torsade de Pointes: ¿un arma terapéutica o etiológica?</dc:title>
<dc:subject>^d3662^s22054</dc:subject>
<dc:subject>^d1150^s22067</dc:subject>
<dc:subject>^d1150^s22012</dc:subject>
<dc:subject>^d2348^s22045</dc:subject>
<dc:subject>^d15100^s22012</dc:subject>
<dc:subject>^d1150^s22016</dc:subject>
<dc:subject>^d30163^s22027</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3662^s22027</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d8453^s22073</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d4667^s22045</dc:subject>
<dc:subject>^d13993^s22012</dc:subject>
<dc:subject>^d29136^s22016</dc:subject>
<dc:subject>^d7186^s22012</dc:subject>
<dc:subject>^d10326^s22066</dc:subject>
<dc:subject>^d10326^s22074</dc:subject>
<dc:subject>^d29136^s22067</dc:subject>
<dc:subject>^d651^s22073</dc:subject>
<dc:subject>^d2348^s22074</dc:subject>
<dc:subject>^d29136^s22054</dc:subject>
<dc:subject>^d29136^s22032</dc:subject>
<dc:type>article</dc:type>
<dc:date>200608</dc:date>
</metadata>
</record>
</ibecs-document>
